About this item:

420 Views | 1 Download

Author Notes:

Correspondence: Donald L. Batisky; Email: dbatisk@emory.edu

Disclosure D. Batisky: research funding from Novartis and Takeda.


Research Funding:

D. Batisky received research funding from Novartis and Takeda.


  • Hypertension
  • Blood pressure
  • Pediatric
  • Children
  • Adolescents
  • Antihypertensive medication
  • Treatment

What Is the Optimal First-Line Agent in Children Requiring Antihypertensive Medication?


Journal Title:

Current Hypertension Reports


Volume 14, Number 6


, Pages 603-607

Type of Work:

Article | Post-print: After Peer Review


There has been an evolution in the understanding of the treatment of hypertension in children and adolescents over the past decade. This has been fueled in part by the increased attention paid to the clinical problem, given the increasing numbers of children and adolescents being diagnosed with this condition. There has also been a growing number of clinical trials performed and completed that demonstrate the blood pressure (BP)-lowering effects of antihypertensives and the side effect profiles of these medications, and that has led to FDA-labeling of many antihypertensive medications for use in children and adolescents. However, none of these trials has provided definitive data on the optimal first line agent for this patient population. Clinical experience and other approaches discussed in this review are still necessary to guide treatment of hypertension in the young. The quest for the optimal antihypertensive agent is just beginning, and it is going to take some extraordinary effort to reach that goal.

Copyright information:

© Springer Science+Business Media, LLC 2012

Export to EndNote